News
QUASAR trial showed Eylea HD matched vision gains of standard Eylea with less frequent dosing. BofA cuts Regeneron price target to $547, maintains Underperform rating. Learn the top momentum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback